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Aim: The PLANET trials showed that atorvastatin 80 mg but not rosuvastatin at
either 10 or 40 mg reduced urinary protein to creatinine ratio (UPCR) at similar
effects on LDL-cholesterol. However, individual changes in both UPCR and LDL-
cholesterol during treatment with these statins varied widely between patients. This
inter-individual variability could not be explained by patients’ physical or biochemical
characteristics. We assessed whether the plasma concentrations of both statins were
associated with LDL-cholesterol and UPCR response.
Materials and methods: The PLANET trials randomized patients with a UPCR of
500-5000 mg/g and fasting LDL-cholesterol >2.33 mmol/L to a 52-week treatment
with atorvastatin 80 mg, rosuvastatin 10 mg or 40 mg. For the current analysis,
patients with available samples at week 52 and treatment compliance >80% by pill
count were included (N = 295). The main outcome measurements were percentage
change in UPCR and absolute change in LDL-cholesterol (delta LDL) from baseline to
week 52.
Results: Median (interquartile range) plasma concentration at week 52 for atorva-
statin 80 mg was 3.9 ng/mL (IQR: 2.1 to 8.7), for rosuvastatin 10 mg 1.0 ng/mL (IQR:
0.7 to 2.0) and for rosuvastatin 40 mg 3.5 ng/mL (IQR: 2.0 to 6.8). Higher plasma
concentration of statin was associated with larger LDL-cholesterol reductions at
week 52 [rosuvastatin r = −0.40 (P < .001); atorvastatin r = −0.28 (P = .006)]. The
plasma concentration of both statins did not correlate with UPCR change
[rosuvastatin r = 0.07 (P = .30); atorvastatin r = 0.16 (P = .13)].
Conclusions: Individual variation in plasma concentrations of rosuvastatin and ator-
vastatin was associated with LDL-cholesterol changes in patients. The individual vari-
ation in UPCR change was not associated with the plasma concentration of both
statins.
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1 | INTRODUCTION
Lipid-lowering therapy is part of the guideline recommended treat-
ment for cardiovascular protection in patients with diabetes and
chronic kidney disease.1 The effects of statins on kidney function
remain unclear. Some studies show a renoprotective profile of a par-
ticular statin whereas other studies have suggested that some statins
may exert harmful effects.2-6
The PLANET trials were designed to assess the effects of atorva-
statin and rosuvastatin on proteinuria and estimated glomerular filtra-
tion rate (eGFR). The trials showed that not all statins are similar in their
effects on renal variables even at equipotent lipid-lowering effects.7
PLANET showed that atorvastatin but not rosuvastatin decreased mean
proteinuria, while mean eGFR decline was less with atorvastatin than
with rosuvastatin despite similar cholesterol-lowering efficacy.7 A post
hoc analysis of these trials showed a large variation in individual patient
responses in proteinuria and lipid variables for both statins, which could
not be explained by clinical patient characteristics.8 Drug concentra-
tions of these statins or their active metabolites have been shown to
play a role in the variation of lipid-lowering effects.9,10 Such data are
not available for the proteinuria response to these statins.
To provide more insight into the underlying mechanisms of the
individual variation in response to statins, we investigated whether
drug plasma concentration of atorvastatin, rosuvastatin or their
metabolites were a determinant of the individual albuminuria and
LDL-cholesterol response. We also assessed which patient character-
istics were associated with the variation in drug concentration.
2 | MATERIALS AND METHODS
2.1 | Study design and protocol
Combined data from the PLANET I and PLANET II trials were used for
this analysis. The design and primary results of both trials were
reported previously.7 In short, the PLANET trials were randomized,
double-blind, 52-week, parallel-group, multicentre, phase 3 studies.
Eligible patients were randomly assigned to treatment with atorva-
statin 80 mg/day, rosuvastatin 10 mg/day or rosuvastatin 40 mg/day
TABLE 1 Demographics and baseline characteristics of the included population. Data are presented as mean (SD) unless otherwise noted.
Plasma concentrations are presented as median and interquartile range
Atorvastatin 80 mg/day Rosuvastatin 10 mg/day Rosuvastatin 40 mg/day
n 92 90 113
Age, years 52.66 (13.64) 55.60 (12.73) 54.04 (12.21)
Gender (female) (%) 29 (31.5) 38 (42.2) 33 (29.2)
Race (%)
Black 6 (10.5) 6 (11.5) 6 (8.7)
Caucasian 48 (84.2) 40 (76.9) 58 (84.1)
Hispanic 3 (5.3) 3 (5.8) 2 (2.9)
Other 0 (0.0) 3 (5.8) 3 (4.3)
BMI 31.19 (8.03) 30.82 (5.87) 30.26 (6.02)
Systolic BP (mm Hg) 138.30 (15.26) 133.73 (16.92) 136.27 (15.45)
Diastolic BP (mm Hg) 81.02 (8.63) 79.00 (8.47) 80.75 (9.40)
eGFR (ml/min/1.73m2) 75.87 (29.51) 75.53 (25.37) 75.93 (28.25)
Total cholesterol (mmol/l) 4.28 (1.40) 4.58 (1.88) 3.93 (1.00)
LDL-cholesterol (mmol/l) 2.14 (1.02) 2.37 (1.65) 1.78 (0.75)
HDL-cholesterol (mmol/l) 1.23 (0.42) 1.36 (0.40) 1.30 (0.41)
Urinary protein to creatinine ratio (mg/g)a 1081 [684-1829] 1074 [694-1807] 1315 [777-1831]
Urinary albumin to creatinine ratio (mg/g)a 852 [456-1296] 813 [538-1333] 965 [616-1418]
Plasma concentration
Rosuvastatin (ng/ml) - 1.03 (0.67-1.97) 3.53 (1.98-6.77)
Atorvastatin (ng/ml) 3.87 (2.05-8.65) - -
Desmethylrosuvastatin (ng/ml) - 0.24 (0.08-0.48) 0.45 (0.21-0.98)
Rosuvastatin lacton (ng/ml) - 0.13 (0.07-0.28) 0.07 (0.04-0.13)
X2-OH-Atorvastatin (ng/ml) 7.38 (2.57-22.1) - -
X4-OH-Atorvastatin (ng/ml) 1.65 (0.70-3.74) - -
Abbreviations: BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate.
aUrinary protein to creatinine ratio and urinary albumin to creatinine ratio are reported as median (IQR).
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for 52 weeks after an 8-week lead-in period in which dietary advice
was given, existing hypertensive treatment was optimized and statins
were discontinued if applicable. The study protocols of the PLANET
trials are registered with clinicaltrials.gov (PLANET I: NCT00296374
and PLANET II: NCT00296400). The trials were performed in accor-
dance with the Declaration of Helsinki and Good Clinical Practice
guidelines. The study protocol was approved by independent ethics
committee. All participants signed written informed consent before
the start of any study-specific procedure.
2.2 | Patients
PLANET I enrolled 325 patients with type 1 or type 2 diabetes and
PLANET II enrolled 220 evaluable patients without diabetes (total
N = 545). Both PLANET trials included patients aged ≥18 years with a
urine protein to creatinine ratio (UPCR) between 500-5000 mg/g and
fasting LDL-cholesterol of 2.33 mmol/L or more, and who were
receiving treatment with an angiotensin converting enzyme (ACE)
inhibitor or angiotensin receptor blocker (ARB) for at least 3 months
before the first screening visit. Key exclusion criteria were
HbA1c ≥ 11%, statin intolerance, severe hypertension and type
3 hyperlipoproteinaemia or if the patient used immunosuppressive
drugs to treat proteinuria or renal disease within 3 months before the
first screening visit. For the current analysis, 295 patients were avail-
able (169 in PLANET I and 126 in PLANET II). In total, 247 patients
were not included for the following reasons: 178 had no plasma
sample available at week 52, 44 did not adhere to therapy (<80%
compliance by pill count) and 25 subjects were excluded for other
reasons.
2.3 | Measurements
Height was collected once at the start of the screening. Vital signs
including blood pressure, weight and pulse rate, urine samples (col-
lected at three consecutive morning voids before the study visit) and
biochemistry, including but not limited to albumin, bilirubin, creatinine,
blood urea nitrogen and a lipid panel consisting of LDL, HDL and total
cholesterol, were collected at baseline and at week 4, 8, 14, 26,
39 and 52 in fasted condition on the morning of the study visit.
At each visit, patients collected three consecutive first morning
void urine samples for measurement of urinary protein, albumin and
creatinine. UPCR and urinary albumin to creatinine ratio (UACR) were
calculated as the geometric mean from the three first morning void
urine collections. The change in UPCR and UACR was defined as the
log ratio of the week 52 value divided by the baseline UPCR or UACR
value. A log transformation was applied to take into account the
skewed distribution. eGFR was calculated with the Modification of
Diet in Renal Disease Equation.11 All clinical chemistry laboratory ana-
lyses were performed at central laboratories (Covance, Indianapolis,
IN, USA, and Geneva, Switzerland).
Plasma concentrations of atorvastatin and rosuvastatin plus
metabolites were measured with liquid chromatography mass
F IGURE 1 Large variation in
plasma concentration between
individuals during treatment with
atorvastatin 80 mg, rosuvastatin
10 mg or rosuvastatin 40 mg
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spectrometry (LC/MS-MS). For atorvastatin and its active metabolites
detection took place using a Sciex API 4000 mass spectrometer in
positive ionization MRM mode. For rosuvastatin and its active metab-
olites detection took place using a Sciex API 6500 mass spectrometer
in positive ionization MRM mode. The mass spectrometric data were
acquired and processed using Analyst (Applied Biosystems). Standard
curves were constructed employing linear regression with 1/x2
weighting. Plasma concentrations of both statins were performed by
QPS (QPS laboratory, Groningen, the Netherlands).
2.4 | Statistical analysis
Changes in UPCR and UACR were calculated as % change and change
in lipids by absolute change both from baseline to end of the study.
We used descriptive statistics to report baseline demographic infor-
mation. Pearson correlation was used to assess the relationship
between drug concentrations of atorvastatin, rosuvastatin and change
in LDL-cholesterol and percentage change UPCR and UACR. Two-
sided P-values <.05 indicated statistical significance.
We imputed missing values of plasma concentrations <LLOQ
(lower limit of quantification) with the lowest measured concentration
below LLOQ. Multiple linear regression models were used to explore
the relationships between the response variable (plasma concentra-
tions) and the explanatory variables (clinical demographics and clinical
chemistry). For the first model, each variable was tested as univariate
and included in the multivariate model when the P-value was ≤.10.
Using backwards elimination and forward inclusion, the best model
was selected. Data were analyzed with R version 3.4.3 (The R Founda-
tion for Statistical Computing Platform: i386-w64-mingw32/i386
[32-bit]). RStudio version 1.1.383 was used.
3 | RESULTS
Clinical and biochemical characteristics as well as statin plasma concentra-
tions are presented in Table 1. The mean eGFR was 76 mL/min/1.73m2
for all three dose groups, median UPCR ranged between 1074 and
1315 mg/g and mean LDL-cholesterol ranged between 1.8 and
2.4 mmol/L for the three dose groups.
Figure 1 shows a wide variation in the plasma concentrations
among individual patients. This was observed for the different statins
and dose groups. The rosuvastatin plasma concentration of 88 patients
assigned to the 10 mg dose (44% of all patients receiving rosuvastatin)
overlapped with the plasma concentration of patients assigned to the
40 mg dose.
The mean change in LDL-cholesterol at week 52 for atorvastatin
80 mg was −2.07 mmol/L (95% CI −4.2 to −0.18 mmol/L) and for the
rosuvastatin group (10 and 40 mg) it was −2.0 mmol/L (95% CI −4.47
to 0.22; Figure 2). The mean change in UPCR at week 52 was −13.2%
(95% CI −24.2 to −0.5) for atorvastatin 80 mg and for the
rosuvastatin (10 and 40 mg) group combined it was 4.1% (95% CI
−7.3 to 16.8; Figure 2). The mean change in UACR at week 52 was
for atorvastatin 80 mg was −19.3% (95% CI −31.2 to −5.3) and for
the rosuvastatin (10 and 40 mg) group combined it was −5.4% (95%
CI −17.2 to 8.1; Figure 2).
To assess whether the exposure of the statins correlated with lipid
and UPCR responses, we correlated the plasma concentration at week
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F IGURE 2 Large variation between individuals in change from
baseline in LDL, urinary protein to creatinine ratio (UPCR) and urinary
albumin to creatinine ratio (UACR) at week 52 during treatment with
atorvastatin 80 mg (A80), rosuvastatin 10 mg (R10) and rosuvastatin
40 mg (R40)
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52 with those responses. Higher plasma concentration of statin was
associated with larger LDL-cholesterol reductions at week
52 [rosuvastatin r = −0.40 (P < .001); atorvastatin r = −0.28 (P = .006);
Table 2]. The variation in plasma concentration of both atorvastatin
and rosuvastatin did not correlate with UPCR or UACR changes
(Table 2 and Figure 3). The metabolites of both statins tended to
correlate with LDL-cholesterol change (Table S1). None of the metab-
olites correlated with UPCR or UACR change.
Finally, we assessed which patient characteristics were associated
with the variation in plasma concentrations of the statins. None of the
assessed patient characteristics were associated with variation in ator-
vastatin plasma concentration (Table 3). For rosuvastatin, lower eGFR
TABLE 2 Pearson correlations between plasma concentrations of atorvastatin and rosuvastatin and delta LDL-cholesterol (mmol/l) and log
delta urinary protein to creatinine ratio (UPCR) and urinary albumin to creatinine ratio (UACR) at week 52
LDL change UPCR change UACR change
Pearson correlation P-value Pearson correlation P-value Pearson correlation P-value
Atorvastatin −0.28 .006 .16 .13 .14 .16
Rosuvastatin −0.40 <.001 .07 .30 .03 .70
F IGURE 3 Plasma concentrations of
atorvastatin (left panels) or rosuvastatin
(right panels, R10 = red, R40 = blue)
correlated with change from baseline in
LDL-cholesterol (top panels) but not with
change from baseline in urinary protein to
creatinine ratio (UPCR) (middle panels)
and urinary albumin to creatinine ratio
(UACR) (bottom panels)
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and higher serum albumin were independently associated with higher
plasma concentration (Table 3).
4 | DISCUSSION
In this study we tested whether the large individual variation in lipid
lowering as well as proteinuria lowering response to two different sta-
tins (atorvastatin and rosuvastatin) was associated with the achieved
individual plasma statin levels in proteinuric patients with or without
diabetes. We found that variations in plasma levels of the statins were
associated with the variation in LDL-cholesterol-lowering effect. The
large variation in proteinuria lowering was not associated with varia-
tions in plasma drug levels of either atorvastatin or rosuvastatin.
The large between-individual variation in plasma concentrations of
atorvastatin and rosuvastatin is consistent with findings from other
statin trials.9,12,13 We found a marked overlap in plasma concentrations
among patients assigned to rosuvastatin 10 mg and 40 mg, indicating
that the individual exposure of a patient at low dose rosuvastatin can
exceed the exposure of an individual treated with a four times higher
dose. These data suggest that individual characteristics determine the
plasma level of a statin. We found that a lower eGFR was associated
with a higher rosuvastatin plasma concentration. Although hepatic
clearance is the major route of rosuvastatin clearance, rosuvastatin is in
part also excreted by the kidneys and the lower eGFR level may reflect
diminished renal clearance. High serum albumin was also associated
with higher plasma concentration. We speculate that because of the
high protein binding of rosuvastatin, the free fraction decreases when
serum albumin increases. As bound rosuvastatin cannot readily leave
the capillaries, total plasma rosuvastatin may increase. As rosuvastatin
is subject to both hepatic and, more importantly, renal elimination, the
potentially lower fraction of unbound drug can also reduce the clear-
ance leading to a higher total plasma concentration of rosuvastatin over
time. Little is known from the literature about the association between
plasma concentration and LDL response at an individual patient level.
Multiple dose finding studies with both atorvastatin and rosuvastatin
have reported strong dose-dependent effects of statins on LDL-choles-
terol.14,15 Specifically, pharmacokinetic studies with rosuvastatin
showed an approximately linear relationship between dose and area
under the rosuvastatin concentration time curve for doses ranging from
5 to 80 mg.16,17 However, these studies assessed the dose exposure
relationship at a population level but not the exposure response at an
individual patient level. We found that lower plasma concentrations of
the statins were associated with a lower LDL-cholesterol response at
an individual patient level. Given that higher doses are associated with
higher plasma concentrations, this finding indicates that to enhance the
LDL-cholesterol-lowering effect a higher dose is probably required.
There are to our knowledge no data in the literature regarding a
dose-response or exposure-response relationship of a statin on protein-
uria lowering (or increase). We found that both statins had clearly vary-
ing effects on proteinuria and albuminuria: atorvastatin lowers both
proteinuria and albuminuria whereas rosuvastatin does not, both mea-
sured at a population level. However, at an individual level, both statins
show a wide range of responses varying from distinct proteinuria low-
ering to increases.8
The potential mechanisms mediating albuminuria-lowering effects
are unclear although various hypotheses have been postulated.
Among other things, it has been suggested that statins may protect
podocytes, reduce endothelial dysfunction, or reduce tubulointerstitial
injury.18
We did not observe a correlation between the individual plasma
concentration of both statins and proteinuria or albuminuria. The
lack of correlation indicates that the systemic exposure is not a
reflection of the individual response. It is possible that intra-renal
exposure is a better indicator of the individual proteinuria response.
Nevertheless, we cannot exclude the possibility that random varia-
tions in proteinuria obscure a true association, although the large
sample size in this study provided sufficient power to detect even
modest correlations.
TABLE 3 Patient characteristics associated with plasma concentrations of atorvastatin 80 mg and rosuvastatin 10 and 40 mg at week 52
Atorvastatin 80 mg/day Rosuvastatin 10 and 40 mg/day
Univariate Multivariate Univariate Multivariate
a
β P-value β P-value β P-value β P-value
Age (per year) .02 .13 - - .01 .20 - -
Gender .31 .40 - - −.31 .27 - -
BMI (baseline) .01 .62 - - .01 .53 - -
Bilirubin (μmol/l) .03 .39 - - .07 .06 - -
eGFR (per ml/min/1.73m2) −.00 .40 - - −.00 .03 −.01 .04
Serum albumin (g/l) −.33 .34 - - .68 .03 .63 .05
Total protein (g/l) .00 .76 - - −.02 .44 - -
Urea nitrogen (mmol/l) .08 .10 - - .09 .01 - -
Note: P-value and β for p-values <0.1 are shown as bold.
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate.
aThe R2 of the multivariate model for rosuvastatin 0.21.
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This study has limitations. First, this was a post hoc exploratory
study. The study was not designed to characterize the statin exposure
and albuminuria response. This is reflected by the fact that dosing
times of individual patients were not available. Although all study
medications were administered as per protocol in the morning and
samples were taken in trough conditions, we are unable to ascertain
the duration between study drug administration and blood sampling.
The current findings should be externally validated or investigated in a
dedicated clinical trial. Second, the variation in plasma concentration
for atorvastatin was smaller than for rosuvastatin because only a sin-
gle dose of atorvastatin was investigated. The smaller inter-individual
variation in plasma concentration of atorvastatin limits the statistical
power to detect an association with pharmacodynamic response vari-
ables. We measured plasma concentrations as a proxy for systemic
exposure. However, the LDL-cholesterol-lowering effect of statins is
caused by the intracellular binding to the HMG-CoA receptor. Intra-
hepatic concentrations of both drugs may have led to stronger associ-
ations with LDL-cholesterol response. Finally, both atorvastatin and
rosuvastatin have active metabolites. Active metabolites were not
associated with LDL-cholesterol response. Because we were not able
to assess the degree of metabolism for both statins at an individual
level, this complicates and possibly underestimates the strength of the
correlation between total active compound of atorvastatin or
rosuvastatin with the pharmacodynamic response.
In conclusion, individual variation in plasma concentrations of both
atorvastatin and rosuvastatin was associated with the variation in
LDL-cholesterol but not proteinuria or albuminuria changes during
treatment with these statins.
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